Cladribine tablets receives positive CHMP opinion...
Posted: Mon Jun 26, 2017 7:18 am
Cladribine tablets receives positive CHMP opinion for treatment of RRMS
Science and technology company, Merck has revealed it has received a positive opinion from the European Medicines Agency (EMA), part of the Committee for Medicinal Products for Human Use (CHMP), for approval of cladribine tablets, also known as Mavenclad. The tablets will be for the treatment of relapsing remitting multiple sclerosis (RRMS) in patients with high disease activity...Read more - http://www.ms-uk.org/cladribine-tablets ... rms-260617
Science and technology company, Merck has revealed it has received a positive opinion from the European Medicines Agency (EMA), part of the Committee for Medicinal Products for Human Use (CHMP), for approval of cladribine tablets, also known as Mavenclad. The tablets will be for the treatment of relapsing remitting multiple sclerosis (RRMS) in patients with high disease activity...Read more - http://www.ms-uk.org/cladribine-tablets ... rms-260617